Agios Pharmaceuticals | AGIO - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 538M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
Arrowhead Research USD 223.22M 10.86M 2025-12
Astellas Pharma JPY 489.36B 52.69B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Bayer EUR 10.33B 126M 2025-12
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Novartis USD 9.8B 61M 2025-12
Novartis USD 9.8B 23M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12